Slide 1: 4Q and FY 2024 Business Update
—_ ~ ocugen. > ee Courageous Innovation Dedicated to Bringing Game-Changing Gene Therapies, Cell Therapies, and Vaccines to Market and Working Even Harder to Provide Access to Patients Globally 4Q and FY 2024 Business Update March 5, 2025
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including, but not limited to, strategy, business plans and objectives for Ocugen’s clinical programs, plans and timelines for the preclinical
Slide 3: Potential for Three Biologics License Applications (BLAs) in the Next Three Years
Potential for Three Biologics License Applications (BLAs) in the Next Three Years p U.S./EU T: t BLA/MAA Product Candidate Status Bice oe ocu400 Phase 3 in Progress Retinids Higmientosa (Ri) (Largest Orphan Gene Therapy 300,000 2026 (Gene-agnostic targeting Clinical Trial) >100 genes, broad indicati
Slide 4: OCU400 First-in-Class Novel Modifier Gene Therapy for RP
OCU400 First-in-Class Novel Modifier Gene Therapy for RP Unmet Need ~300,000 people in the U.S./EU and 1.6 million globally suffer from RP, which affects >100 genes. One approved product (Luxturna®), a gene therapy, which can OCU40O0 Market Potential address only one gene (RPE65). | Luxturna peak an
Slide 5: Durability of Visual Function (LLVA) - Long-Term Follow-up
Durability of Visual Function (LLVA) - Long-Term Follow-up Multiple Mutations* (N=10) RHO(N=8) pati = 0.088 * 100% (10/10) treated evaluable subjects showed 2 40 : 2 404° improvement or preservation in visual function 3 p=0.005 | p=0.005 é = & * compared to untreated eyes 5 25 = 5 = * Treated eyes w
Slide 6: OCU400 Phase 3 liMeliGhT Trial: Design and Key Criteria
OCU400 Phase 3 liMeliGhT Trial: Design and Key Criteria OCU400 Phase 3 MTD established from Phase 1/2 trial Randomization 2:1 (RHO, Gene-agn Arms Dose Control Group Gene-agnostic, n=25) No treatment Treatment Group 2.5x10"° vg/eye in 250 pL — ocugen. <e Study Endpoints Primary Efficacy Endpoint * Ch
Slide 7: OCU410ST First-in-Class Novel Modifier Gene Therapy Product for Stargardt Disease
OCU410ST First-in-Class Novel Modifier Gene Therapy Product for Stargardt Disease Unmet Need ~100,000 people in U.S./EU and 1 million globally suffer from ABCA4-associated retinopathies' (>1,200 mutations). Currently there are no approved products in the market. Potential Solution OCU410ST has poten
Slide 8: Improvement of Visual Function in OCU410ST Treated vs Untreated Eyes
Improvement of Visual Function in OCU410ST Treated vs Untreated Eyes 10 < 2 -@ TreatedEye -® Untreated Eye oo 5 — * 6/6 (100%) evaluable treated eyes Eg (ne from Baseline Hi £o } demonstrated improvement or OE 1 stabilization in visual function ce = _ ee Stabilizati . 5 a Baseline ~—_ Ms Me |] Stept
Slide 9: • • • • • 6M 0.0 0.2 0.4 0.6 Timeline Treated Eye Untreated
• • • • • 6M 0.0 0.2 0.4 0.6 Timeline Treated Eye Untreated Eye 52%
Slide 10: Clinical Study Design for Phase 2/3 Pivotal Confirmatory BLA Trial
Clinical Study Design for Phase 2/3 Pivotal Confirmatory BLA Trial Phase 2/3 Pivotal Confirmatory BLA Trial Study Endpoints MTD established from Phase 1 trial Primary Efficacy Endpoint: * Change from baseline to Month 12 in the atrophic lesion size [measured in mm? by fundus autofluorescence (FAF)]
Slide 11: OCU410 First-in-Class Novel Modifier Gene Therapy for GA
OCU410 First-in-Class Novel Modifier Gene Therapy for GA Unmet Need ~19 million people in U.S. and EU and 260 million globally suffer from dAMD' ~2-3 million people in U.S. & EU and ~8 million globally suffer from GA-—advanced dAMD2 * 2approved products for GA: Ci h d prod I di hy iated with GA and
Slide 12: Preservation of Visual Function (LLVA) in OCU410 Treated vs Untreated Eyes
Preservation of Visual Function (LLVA) in OCU410 Treated vsUntreated Eyes in Phase 1/2 Study Pa 5 53 aa 0 Stabilization Treated eyes demonstrate & 2-line (10-letter*) gain in Po 5 Decrease visual acuity when 2s | from Bassline compared to untreated 2 10 fellow eyes ca 35 -e- Treated Eye — ocugen. —
Slide 13: Substantial Slowing of GA Lesion Growth after Single Sub-Retinal Injection of OCU410
Substantial Slowing of GA Lesion Growth after Single Sub-Retinal Injection of OCU410 oe ~~ Natural History Studies —* Untreated Eye -* Treated Eye 1694039 ° 44% slower GA lesion growth in 4 treated eye versus fellow eyes a after single injection 0.95#0.45 nN ¢ The slope of the untreated eye overlaps
Slide 14: OCU410 Treatment Preserves Retinal Tissue in GA Lesions
OCU410 Treatment Preserves Retinal Tissue in GA Lesions ° a ° B Pere eer Single sub-retinal injection of OCU410 at 9M is more effective when compared to PM and PEOM treatment ° ® Ser Seema Beers 9° ib 2 0.7 0.375 PEOM (9M) PM (9M) 0CU410(9M) Difference in Mean GA lesion Size between Treated and Untr
Slide 15: OCU410 Phase 2 Study: Design and Key Criteria
OCU410 Phase 2 Study : Design and Key Criteria Phase 2 Study Endpoints MTD established Primary Endpoint * Change in GA lesion size (mm2) using Fundus Autofluorescence Randomization 1:1:1 Medium-dose High-dose Group cup Control Group n=i7 ni? n=17 Secondary Endpoint * Change in LLVA up to M12 * Prese
Slide 16: OCU410 is Relatively Safe Compared to Approved Drugs for GA
OCU410 is Relatively Safe Compared to Approved Drugs for GA [Competitor] Ocua10 | Endophthalmitis and Retinal Detachments Retinal Vasculitis and/or Retinal Vascular Occlusion Choroidal Neovascularization Intraocular Inflammation Optic ischemic neuropathy Treatment Emergent Serious Adverse Events — ~
Slide 17: OCU200 & OCU500
OCU200 & OCUSOO ¢ OCU200 OCUSOO — ocugen. wees Therapeutic Focus: diabetic macular edema (DME), diabetic retinopathy (DR), and wet AMD: total prevalence = 130 million Differentiator: Targets underlying disease mechanisms through the integrin pathway and holds promise to provide benefit to all DME pa
Slide 18: Financial Update
Financial Update
Slide 19: Financial Update
Financial Update Three months ended Year ended Statement of Operations December 31, December 31, 2024 2023 2024 2023 Research and development expense $8.3 $7.8 $32.1 $39.6 General and administrative expense 63 52) 26.7 32.0 Other income (expense), net 0.0 0.6 0.7 25 Net loss $013.9) ($11.0) $54.1) $
Slide 20: Questions & Answers
Questions & Answers
Slide 21: Near-Term Targeted Milestones—2025
Near-Term Targeted Milestones—2025 * Complete OCU400 Phase 3 recruitment and continue to monitor patients to ensure BLA/MAA filings are complete in mid-2026 * Provide safety and efficacy updates from OCU410 Phase | and Phase 2 (interim) * — Initiate OCU410ST Phase 2/3 pivotal confirmatory clinical t
Slide 22: Ocugen Vision
Ocugen” Vision Fully integrated, patient-centric biotech company focused on vaccines in support of public health and gene and cell therapies targeting unmet medical needs through Courageous Innovation — ocugen. wees 22